{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-22-000277","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.250698+00:00","generated_at":"2026-06-21T05:48:04.121677+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Lilly guides 2023 revenue $30.3B-$30.8B, EPS $7.65-$7.85; plans four new drug launches","bullets":["2023 revenue guidance $30.3B-$30.8B, up from 2022 reaffirmed $28.5B-$29.0B.","2023 reported EPS $7.65-$7.85; non-GAAP EPS $8.10-$8.30; 2022 reaffirmed $6.50-$6.65 reported.","Plans to launch donanemab, mirikizumab, lebrikizumab, pirtobrutinib; potential tirzepatide obesity submission.","Fifth consecutive 15% annual dividend increase; R&D spend $8.2B-$8.4B vs $7.1B-$7.3B 2022.","Gross margin ~77% reported, ~79% non-GAAP; tax rate ~16%; Alimta LOE and FX headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-22-000277","json":"https://secwatch.observer/filing/0000059478-22-000277.json","markdown":"https://secwatch.observer/filing/0000059478-22-000277.md","text":"https://secwatch.observer/filing/0000059478-22-000277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/lly-20221213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:48:04.121677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7342896d09d00a014a1b16ad46db36bf6406da74","claim":"ELI LILLY & Co reported FY2023 results: revenue $30.3 billion to $30.8 billion, EPS $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.","evidence_excerpt":"2023 revenue expected to be between $30.3 billion and $30.8 billion, driven by key growth products. • 2023 EPS expected to be in the range of $7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023"},{"label":"Revenue","value":"$30.3 billion to $30.8 billion"},{"label":"EPS","value":"$7.65 to $7.85 on a reported basis and $8.10 to $8.30 on a non-GAAP basis"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d03ee7457d2f4993318189a260de1b1f8edc038d","claim":"ELI LILLY & Co reported FY2022 results: revenue $28.5 to $29.0 billion, EPS $6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis. Guidance reaffirmed.","evidence_excerpt":"IPR&D or development milestone charges incurred during Q4 2022. 2 The company reaffirmed its 2022 financial guidance, as set forth in the following table: 2022 Guidance Revenue $28.5 to $29.0 billion Gross Margin % of Revenue (reported) Approx. 76% Gross Margin % of Revenue (non-GAAP) Approx. 78% Marketing, Selling & Administrative $6.4 to $6.6 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/59478/000005947822000277/0000059478-22-000277-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2022"},{"label":"Revenue","value":"$28.5 to $29.0 billion"},{"label":"EPS","value":"$6.50 to $6.65 on a reported basis and $7.70 to $7.85 on a non-GAAP basis"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}